Pradeep Nathan read pharmacology and neuroscience at the University of Melbourne followed by a PhD in experimental medicine. He is Vice President of Central Nervous System (CNS) Clinical Development and Head of Experimental Medicine for Sosei Heptares (formally Heptares Therapeutics). He is an Affiliated Lecturer in the Department of Psychiatry at the University of Cambridge and Adjunct Professor at Neuroscience at Monash University, Australia.
Pradeep has over 10 years of experience working in drug development and during this time played a significant leadership role in the pre-clinical, early-clinical development and experimental medicine strategy and execution of translational and clinical studies for a number of CNS targets. These include M1 agonist, H3 antagonist, D3 antagonist, 5-HT6 antagonist, Mu-opioid receptor antagonist, COMT inhibitor, Orexin 1 antagonist and D1 PAM for a number of indications including Alzheimer's disease, schizophrenia, Parkinson's disease, obesity and addiction. He is currently leading the experimental medicine and early-clinical development of compounds targeting muscarinic M1 and M4, mGlu5, and Orexin 1 receptors for various CNS indications.
Pradeep has also contributed to medical sciences and drug discovery/development through his significant contributions to scientific peer review and working across industry/academia boundaries to facilitate translational neuroscience and drug discovery/development efforts. He has been a member of the MRC's Developmental pathway funding scheme, Therapeutic target validation mental health and Industry asset sharing panels over the last five years and acted as a key opinion leader and advisor for the MRC's five-year mental health strategy. He has also been part of a Europeean-wide working group that brought together stakeholders from academia, industry and regulatory agencies to address many challenges in psychiatric drug development and stimulate research and development activity within industry.